Skip to content

Valneva Covid Vaccine Neutralizes Omicron in Early Lab Tests

  • A third dose of the shot created antibodies in most volunteers
  • Vaccine expected to be authorized in Europe, U.K. this quarter
Video player cover image
How the Global Vaccine Campaign Has Succeeded—and Failed
Updated on

French drugmaker Valneva SE said a third dose of its Covid-19 vaccine neutralizes the omicron variant in early lab studies, boosting the prospects of the shot as it seeks regulatory authorization.

Blood from 30 trial participants found that 26 produced neutralizing antibodies against omicron after a booster shot, with all 30 creating antibodies against the delta strain, the company said in a statement Wednesday. Relative to the original strain, neutralization was 2.7-fold lower for delta and 16.7-fold lower for omicron, Valneva said.